CKAP2与恶性肿瘤

doi:10.16352/j.issn.1001-6325.2024.10.1470

摘要/Abstract

摘要： 细胞骨架相关蛋白2(CKAP2)基因位于人染色体13q14.3上,编码细胞骨架相关蛋白2,参与调控有丝分裂染色体的分离。CKAP2在多项研究中被证实是一个促癌基因,能调控JAK2/ STAT3、FAK-ERK2和NF-κB等信号通路影响肿瘤细胞的增殖、凋亡、侵袭等生物学行为,改变肿瘤微环境、调节肿瘤免疫。CKAP2还与有丝分裂中纺锤体的形成密切相关,CKAP2失调会导致染色体的错误分离,促进肿瘤的发生。此外,CKAP2与肿瘤的化疗耐药性密切相关,相关机制尚不明确。CKAP2或许能成为一个新型的肿瘤标志物和有效的治疗靶点,在肿瘤的诊断及其治疗方面发挥重要作用。

关键词: 细胞骨架相关蛋白2, 肿瘤, 有丝分裂

Abstract: Cytoskeleton-associated protein 2 (CKAP2) gene is located on human chromosome 13q14.3 and encodes cytoskeleton associated protein 2, which is involved in regulating the separation of mitotic chromosomes. CKAP2 has been confirmed in multiple studies to be an oncogenic gene that can regulate JAK2/STAT3, FAK-ERK2, and NF-κB signaling pathway affects the biological behaviors of tumor cells such as proliferation, apoptosis, and invasion, alters the tumor microenvironment, and regulates tumor immunity. CKAP2 is also closely related to the formation of spindle bodies during mitosis, and dysregulation of CKAP2 can lead to incorrect chromosome separation, promoting tumor development. In addition, CKAP2 is closely related to chemotherapy resistance in tumors, and the underlying mechanisms are not yet clear.CKAP2 may become a novel tumor marker and effective therapeutic target, playing an important role in the diagnosis and treatment of tumors.

Key words: cytoskeleton-associated protein 2(CKAP2), tumor, mitosis

中图分类号:

林港回, 蔡炳君, 周宇. CKAP2与恶性肿瘤[J]. 基础医学与临床, 2024, 44(10): 1470-1473.

参考文献

[1]Yoo BH, Kang DS, Park CH, et al. CKAP2 phosphorylation by CDK1/cyclinB1 is crucial for maintaining centrosome integrity[J]. Exp Mol Med, 2017, 49: e354. doi:10.1038/emm.2017.92.
[2]Hong KU, Kim E, Bae CD, et al. TMAP/CKAP2 is essential for proper chromosome segregation[J]. Cell Cycle, 2009, 8: 314-324. doi:10.4161/cc.8.2.7597.
[3]Yumoto T, Nakadate K, Nakamura Y, et al. Radmis, a novel mitotic spindle protein that functions in cell division of neural progenitors[J]. PLoS One, 2013, 8: e79895. doi:10.1371/journal.pone.0079895.
[4]Venkitaraman AR. Chromosomal instability in cancer: causality and interdependence[J]. Cell Cycle, 2007, 6: 2341-2343. doi:10.4161/cc.6.19.4753.
[5]Kang DS, Hong KM, Park J, et al. Cyclin A regulates a cell-cycle-dependent expression of CKAP2 through phosphorylation of Sp1[J]. Biochem Biophys Res Commun, 2012, 420: 822-827. doi:10.1016/j.bbrc.2012.03.081.
[6]Dos Santos A, Ouellete G, Diorio C, et al. Knockdown of CKAP2 inhibits proliferation, migration, and aggregate formation in aggressive breast cancer[J]. Cancers (Basel), 2022, 14: 3759. doi:10.3390/cancers14153759.
[7]Ma HN, Chen HJ, Liu JQ, et al. Long non-coding RNA DLEU1 promotes malignancy of breast cancer by acting as an indispensable coactivator for HIF-1α-induced transcription of CKAP2[J]. Cell Death Dis, 2022, 13: 625. doi:10.1038/s41419-022-04880-z.
[8]Ghosh S, Javia A, Shetty S, et al. Triple negative breast cancer and non-small cell lung cancer: clinical challenges and nano-formulation approaches[J]. J Control Release, 2021, 337: 27-58. doi:10.1016/j.jconrel.2021.07.014.
[9]Yin L, Duan JJ, Bian XW, et al. Triple-negative breast cancer molecular subtyping and treatment progress[J]. Breast Cancer Res, 2020, 22: 61. doi:10.1186/s13058-020-01296-5.
[10]Jin XX, Mei YN, Shen Z, et al. A chalcone-syringaldehyde hybrid inhibits triple-negativebreast cancer cell proliferation and migration by inhibiting CKAP2-mediated FAK and STAT3 phosphorylation[J]. Phytomedicine, 2022, 101: 154087. doi:10.1016/j.phymed.2022.154087.
[11]张昌生, 张学贞, 韩宗明, 等. 沉默细胞骨架相关蛋白2抑制肝癌细胞增殖和迁移并促进细胞凋亡[J]. 中南大学学报(医学版), 2020, 45: 365-371. doi:10.11817/j.issn.1672-7347.2020.180798.
[12]Feng Y, Wei G, Zhang L, et al. LncRNA DARS-AS1 aggravates the growth and metastasis of hepatocellular carcinoma via regulating the miR-3200-5p-Cytoskeleton associated protein 2 (CKAP2) axis[J]. Bioengineered, 2021, 12: 8217-8232. doi:10.1080/21655979.2021.1982272.
[13]Zhang M, Zhao L. CKAP2 promotes ovarian cancer proliferation and tumorigenesis through the FAK-ERK pathway[J]. DNA Cell Biol, 2017, 36: 983-990. doi:10.1089/dna.2017.3876.
[14]Gao Y, Liu X, Li T, et al. Cross-validation of genes potentially associated with overall survival and drug resis-tance in ovarian cancer[J]. Oncol Rep, 2017, 37: 3084-3092. doi:10.3892/or.2017.5534.
[15]Kim YW, Eom BW, Kook MC, et al. Clinical implications of proliferation activity in T1 or T2 male gastric cancer patients[J]. Exp Mol Med, 2015, 47: e193. doi:10.1038/emm.2015.79.
[16]Rajaram S, Gupta B. Screening for cervical cancer: choices & dilemmas[J]. Indian J Med Res, 2022, 2: 210-220. doi:10.4103/ijmr.IJMR_857_20.
[17]Guo QS, Song Y, Hua KQ, et al. Involvement of FAK-ERK2 signaling pathway in CKAP2-induced proliferation and motility in cervical carcinoma cell lines[J]. Sci Rep, 2017, 7: 2117. doi:10.1038/s41598-017-01832-y.
[18]He L, Li H, Wu A, et al. Functions of N6-methyladenosine and its role in cancer[J]. Mol Cancer, 2019, 18: 176. doi:10.1186/s12943-019-1109-9.
[19]Zhang Y, Chen X, Chen H, et al. ZC3H13 enhances the malignancy of cervical cancer by regulating m6A modification of CKAP2[J]. Crit Rev Immunol, 2023, 43: 1-13. doi:10.1615/CritRevImmunol.2023049342.
[20]Guo L, Li C, Guo J, et al. CKAP2 promotes cervical cancer progression by modulating the tumor microenvironment via NF-κB signaling[J]. Am J Cancer Res, 2023, 13: 2376-2391.
[21]Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer[J]. Pharmacol Ther, 2021, 221: 107753. doi:10.1016/j.pharmthera.2020.107753.
[22]Zhang S, Li N, Yang Y, et al. CKAP2 overexpression correlates with worse overall survival in patients with lung adenocarcinoma[J]. Medicine (Baltimore), 2022, 101: e29796. doi:10.1097/md.0000000000029796.
[23]Wang K, Huang R, Li G, et al. CKAP2 expression is associated with glioma tumor growth and acts as a prognostic factor in high-grade glioma[J]. Oncol Rep, 2018, 40: 2036-2046. doi:10.3892/or.2018.6611.
[24]Zhang S, Wang Y, Chen S, et al. Silencing of cytoskeleton-associated protein 2 represses cell proliferation and induces cell cycle arrest and cell apoptosis in osteosarcoma cells[J]. Biomed Pharmacother, 2018, 106: 1396-1403. doi:10.1016/j.biopha.2018.07.104.
[25]Jia W, Wang C. KNTC1 and MCM2 are the molecular targets of gallbladder cancer[J].Aging, 2023, 15: 7008. doi:10.18632/aging.204889.